<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01273259</url>
  </required_header>
  <id_info>
    <org_study_id>CHUBX 2003/04</org_study_id>
    <nct_id>NCT01273259</nct_id>
  </id_info>
  <brief_title>Study of Dehydroepiandrosterone (DHEA) in Respiratory Pulmonary Hypertension in Adults</brief_title>
  <official_title>Study of Dehydroepiandrosterone (DHEA) in Respiratory Pulmonary Hypertension in Adults. Phase 2 Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Bordeaux</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Bordeaux</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      DHEA prevents and reverses chronic hypoxic pulmonary hypertension in a chronic
      hypoxic-pulmonary hypertension model in the rat. However, no study has been performed in
      human. The purpose of this study is to determine if DHEA is effective in the treatment of
      respiratory pulmonary hypertension in adults with Chronic Obstructive Pulmonary Disease
      (COPD) on exercise capacity and haemodynamic variables. Patients will receive after
      randomisation either 25 mg/day or 200mg/day oral DHEA over a one-year period. Evaluation
      concerns clinical parameters, echocardiography and right catheterization after and before
      treatment. Primary end-point is the six-minute walk test. This is a prospective double blind,
      randomised, placebo controlled study which will be realized in four university hospitals in
      France : Bordeaux, Strasbourg, Toulouse and Limoges.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>January 2011</start_date>
  <primary_completion_date type="Anticipated">March 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy of DHEA on exercise capacity (six-minute walk test)</measure>
    <time_frame>inclusion and one year of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pulmonary and systemic arterial pressures (mean, systolic and diastolic)</measure>
    <time_frame>Inclusion and after one year of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary vascular resistances</measure>
    <time_frame>Inclusion and after one year of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety / Compliance</measure>
    <time_frame>along one year of treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">8</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <condition>Hypertension, Pulmonary</condition>
  <arm_group>
    <arm_group_label>200 mg /day arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>25 mg/day arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DHEA Treatment</intervention_name>
    <description>DHEA : 200 mg/day hard gelatine capsule</description>
    <arm_group_label>200 mg /day arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DHEA Treatment</intervention_name>
    <description>DHEA : 25 mg/day hard gelatine capsule</description>
    <arm_group_label>25 mg/day arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 18 years old and ≤ 75 years old

          -  Chronic Obstructive Pulmonary Disease with FEVs/VC &lt; 70% (*)

          -  Respiratory pulmonary hypertension with mean pulmonary arterial pressure ≥ 20 mmHg (*)
             related to normal pulmonary capillar pressure assessed by catheterization of the right
             side of the heart (pulmonary capillary wedge pressure ≤12mmHg)

          -  PO2 ≤ 70 mmHg assessed by arterial gasometry at ease

          -  If oxygenotherapy then oxygenotherapy more than 6 months before pre-screening

          -  Written informed consent

        (*) Criteria assessed from last health check or the last exams for COPD diagnosis

        Exclusion Criteria:

          -  clinical instability and/or respiratory exacerbation dangerous for catheterization

          -  Pregnancy (ßHCG &gt; 20 UI /l) or breastfeeding on going

          -  General corticotherapy &gt; 0,5 mg/kg/day prednisolon equivalent

          -  Hepatic insufficiency (TP &lt; 50%) or renal insufficiency (creatininemia &gt; 130 µmol/l)
             or diabetes mellitus type I or II (treated by oral antidiabetic or insulin)

          -  Left-heart failure (coronary heart disease and/or left valvulopathy)

          -  High level of prostatic specific antigen (PSA) (&gt; 7ng/ml)

          -  Cancer antecedent or treatment on going
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Eric Dumas De La Roque, Dr</last_name>
    <email>eric.dumas-de-la-roque@chu-bordeaux.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Fabienne Nacka, phD</last_name>
    <email>fabienne.nacka@chu-bordeaux.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital, Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Claire Dromer, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Douard, Pr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marc Billes, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rean, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Benissan, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bui, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Limoges</name>
      <address>
        <city>Limoges</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Toulouse</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 7, 2011</study_first_submitted>
  <study_first_submitted_qc>January 7, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 10, 2011</study_first_posted>
  <last_update_submitted>January 7, 2011</last_update_submitted>
  <last_update_submitted_qc>January 7, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 10, 2011</last_update_posted>
  <responsible_party>
    <name_title>Jean-Pierre LEROY / Clinical Research and Innovation Director</name_title>
    <organization>University Hospital, Bordeaux</organization>
  </responsible_party>
  <keyword>Hypertension, pulmonary</keyword>
  <keyword>DHEA</keyword>
  <keyword>six-minute walk test</keyword>
  <keyword>pulmonary arterial pressure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
    <mesh_term>Hypertension, Pulmonary</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dehydroepiandrosterone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

